Is LAB or OABI more profitable?

Standard BioTools has a net margin of 100.36% compared to OmniAb's net margin of -115.12%. Standard BioTools' return on equity of -7.57% beat OmniAb's return on equity. Company Net Margins Return on Equity Return on Assets Standard BioTools 100.36% -7.57% -6.14% OmniAb -115.12% -16.59% -14.82%

Which has better valuation & earnings, EVO or LAB?

Standard BioTools has lower revenue, but higher earnings than Evotec. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Evotec $891.97M 0.64 -$117.12M N/A N/A Standard BioTools $85.33M 3.54 -$74.90M $0.22 3.50

Is EVO or LAB more profitable?

Standard BioTools has a net margin of 100.36% compared to Evotec's net margin of -26.20%. Standard BioTools' return on equity of -7.57% beat Evotec's return on equity. Company Net Margins Return on Equity Return on Assets Evotec -26.20% -24.93% -11.35% Standard BioTools 100.36% -7.57% -6.14%

Standard BioTools (LAB) Competitors

$0.77 +0.04 (+5.45%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$0.76 0.00 (-0.62%)

As of 09/18/2026 07:30 PM Eastern

Compare

LAB vs. CYRX, MLAB, CTKB, OABI, and EVO

Should you buy Standard BioTools stock or one of its competitors? Standard BioTools's main competitors and comparable companies include CryoPort (CYRX), Mesa Laboratories (MLAB), Cytek Biosciences (CTKB), OmniAb (OABI), and Evotec (EVO). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "life sciences tools & services" industry.

How does Standard BioTools compare to CryoPort?

Standard BioTools (NASDAQ:LAB) and CryoPort (NASDAQ:CYRX) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their valuation, earnings, profitability, dividends, risk, institutional ownership, media sentiment and analyst recommendations.

In the previous week, CryoPort had 4 more articles in the media than Standard BioTools. MarketBeat recorded 4 mentions for CryoPort and 0 mentions for Standard BioTools. CryoPort's average media sentiment score of 0.95 beat Standard BioTools' score of 0.00 indicating that CryoPort is being referred to more favorably in the news media.

Company	Overall Sentiment
Standard BioTools	Neutral
CryoPort	Positive

Standard BioTools presently has a consensus price target of $1.35, indicating a potential upside of 75.37%. CryoPort has a consensus price target of $18.00, indicating a potential upside of 5.76%. Given Standard BioTools' higher probable upside, analysts clearly believe Standard BioTools is more favorable than CryoPort.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Standard BioTools	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67
CryoPort	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.67

Standard BioTools has a net margin of 100.36% compared to CryoPort's net margin of -20.05%. CryoPort's return on equity of -7.20% beat Standard BioTools' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Standard BioTools	100.36%	-7.57%	-6.14%
CryoPort	-20.05%	-7.20%	-4.30%

Standard BioTools has a beta of 1.37, indicating that its share price is 37% more volatile than the broader market. Comparatively, CryoPort has a beta of 1.89, indicating that its share price is 89% more volatile than the broader market.

CryoPort has higher revenue and earnings than Standard BioTools. CryoPort is trading at a lower price-to-earnings ratio than Standard BioTools, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Standard BioTools	$85.33M	3.54	-$74.90M	$0.22	3.50
CryoPort	$176.18M	4.89	$78.30M	-$0.90	N/A

53.7% of Standard BioTools shares are owned by institutional investors. Comparatively, 92.9% of CryoPort shares are owned by institutional investors. 26.8% of Standard BioTools shares are owned by company insiders. Comparatively, 9.5% of CryoPort shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Summary

CryoPort beats Standard BioTools on 11 of the 16 factors compared between the two stocks.

How does Standard BioTools compare to Mesa Laboratories?

Standard BioTools (NASDAQ:LAB) and Mesa Laboratories (NASDAQ:MLAB) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, media sentiment, valuation, earnings, analyst recommendations, dividends, institutional ownership and risk.

In the previous week, Mesa Laboratories had 1 more articles in the media than Standard BioTools. MarketBeat recorded 1 mentions for Mesa Laboratories and 0 mentions for Standard BioTools. Mesa Laboratories' average media sentiment score of 1.82 beat Standard BioTools' score of 0.00 indicating that Mesa Laboratories is being referred to more favorably in the news media.

Company	Overall Sentiment
Standard BioTools	Neutral
Mesa Laboratories	Very Positive

Standard BioTools has a beta of 1.37, suggesting that its share price is 37% more volatile than the broader market. Comparatively, Mesa Laboratories has a beta of 0.97, suggesting that its share price is 3% less volatile than the broader market.

53.7% of Standard BioTools shares are owned by institutional investors. Comparatively, 90.6% of Mesa Laboratories shares are owned by institutional investors. 26.8% of Standard BioTools shares are owned by insiders. Comparatively, 2.8% of Mesa Laboratories shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Standard BioTools has a net margin of 100.36% compared to Mesa Laboratories' net margin of 1.92%. Mesa Laboratories' return on equity of 22.72% beat Standard BioTools' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Standard BioTools	100.36%	-7.57%	-6.14%
Mesa Laboratories	1.92%	22.72%	9.82%

Mesa Laboratories has higher revenue and earnings than Standard BioTools. Standard BioTools is trading at a lower price-to-earnings ratio than Mesa Laboratories, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Standard BioTools	$85.33M	3.54	-$74.90M	$0.22	3.50
Mesa Laboratories	$249.13M	2.84	$6.71M	$0.84	150.64

Standard BioTools currently has a consensus target price of $1.35, indicating a potential upside of 75.37%. Mesa Laboratories has a consensus target price of $110.00, indicating a potential downside of 13.07%. Given Standard BioTools' higher possible upside, analysts clearly believe Standard BioTools is more favorable than Mesa Laboratories.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Standard BioTools	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67
Mesa Laboratories	0 Sell rating(s)	3 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

Mesa Laboratories beats Standard BioTools on 10 of the 15 factors compared between the two stocks.

How does Standard BioTools compare to Cytek Biosciences?

Cytek Biosciences (NASDAQ:CTKB) and Standard BioTools (NASDAQ:LAB) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, profitability, risk, earnings, institutional ownership, media sentiment, analyst recommendations and dividends.

Cytek Biosciences currently has a consensus price target of $5.56, indicating a potential upside of 4.95%. Standard BioTools has a consensus price target of $1.35, indicating a potential upside of 75.37%. Given Standard BioTools' higher possible upside, analysts plainly believe Standard BioTools is more favorable than Cytek Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cytek Biosciences	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33
Standard BioTools	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67

In the previous week, Cytek Biosciences had 2 more articles in the media than Standard BioTools. MarketBeat recorded 2 mentions for Cytek Biosciences and 0 mentions for Standard BioTools. Cytek Biosciences' average media sentiment score of 0.26 beat Standard BioTools' score of 0.00 indicating that Cytek Biosciences is being referred to more favorably in the media.

Company	Overall Sentiment
Cytek Biosciences	Neutral
Standard BioTools	Neutral

69.5% of Cytek Biosciences shares are owned by institutional investors. Comparatively, 53.7% of Standard BioTools shares are owned by institutional investors. 10.4% of Cytek Biosciences shares are owned by insiders. Comparatively, 26.8% of Standard BioTools shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Cytek Biosciences has a beta of 1.18, indicating that its share price is 18% more volatile than the broader market. Comparatively, Standard BioTools has a beta of 1.37, indicating that its share price is 37% more volatile than the broader market.

Cytek Biosciences has higher revenue and earnings than Standard BioTools. Cytek Biosciences is trading at a lower price-to-earnings ratio than Standard BioTools, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cytek Biosciences	$201.49M	3.42	-$66.54M	-$0.62	N/A
Standard BioTools	$85.33M	3.54	-$74.90M	$0.22	3.50

Standard BioTools has a net margin of 100.36% compared to Cytek Biosciences' net margin of -38.98%. Standard BioTools' return on equity of -7.57% beat Cytek Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cytek Biosciences	-38.98%	-12.40%	-9.17%
Standard BioTools	100.36%	-7.57%	-6.14%

Summary

Standard BioTools beats Cytek Biosciences on 9 of the 16 factors compared between the two stocks.

How does Standard BioTools compare to OmniAb?

Standard BioTools (NASDAQ:LAB) and OmniAb (NASDAQ:OABI) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, profitability, earnings, dividends, risk, valuation and media sentiment.

Standard BioTools currently has a consensus target price of $1.35, suggesting a potential upside of 75.37%. OmniAb has a consensus target price of $11.00, suggesting a potential upside of 146.09%. Given OmniAb's stronger consensus rating and higher probable upside, analysts plainly believe OmniAb is more favorable than Standard BioTools.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Standard BioTools	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67
OmniAb	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

Standard BioTools has a net margin of 100.36% compared to OmniAb's net margin of -115.12%. Standard BioTools' return on equity of -7.57% beat OmniAb's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Standard BioTools	100.36%	-7.57%	-6.14%
OmniAb	-115.12%	-16.59%	-14.82%

53.7% of Standard BioTools shares are owned by institutional investors. Comparatively, 72.1% of OmniAb shares are owned by institutional investors. 26.8% of Standard BioTools shares are owned by company insiders. Comparatively, 9.8% of OmniAb shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

OmniAb has lower revenue, but higher earnings than Standard BioTools. OmniAb is trading at a lower price-to-earnings ratio than Standard BioTools, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Standard BioTools	$85.33M	3.54	-$74.90M	$0.22	3.50
OmniAb	$18.67M	34.66	-$64.78M	-$0.36	N/A

Standard BioTools has a beta of 1.37, meaning that its stock price is 37% more volatile than the broader market. Comparatively, OmniAb has a beta of 0.62, meaning that its stock price is 38% less volatile than the broader market.

In the previous week, OmniAb had 2 more articles in the media than Standard BioTools. MarketBeat recorded 2 mentions for OmniAb and 0 mentions for Standard BioTools. OmniAb's average media sentiment score of 0.60 beat Standard BioTools' score of 0.00 indicating that OmniAb is being referred to more favorably in the news media.

Company	Overall Sentiment
Standard BioTools	Neutral
OmniAb	Positive

Summary

Standard BioTools and OmniAb tied by winning 8 of the 16 factors compared between the two stocks.

How does Standard BioTools compare to Evotec?

Evotec (NASDAQ:EVO) and Standard BioTools (NASDAQ:LAB) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, valuation, profitability, analyst recommendations, institutional ownership, risk, media sentiment and dividends.

Evotec currently has a consensus price target of $3.00, indicating a potential upside of 87.50%. Standard BioTools has a consensus price target of $1.35, indicating a potential upside of 75.37%. Given Evotec's stronger consensus rating and higher probable upside, research analysts plainly believe Evotec is more favorable than Standard BioTools.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Evotec	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Standard BioTools	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67

Evotec has a beta of 1.92, suggesting that its stock price is 92% more volatile than the broader market. Comparatively, Standard BioTools has a beta of 1.37, suggesting that its stock price is 37% more volatile than the broader market.

Standard BioTools has lower revenue, but higher earnings than Evotec.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Evotec	$891.97M	0.64	-$117.12M	N/A	N/A
Standard BioTools	$85.33M	3.54	-$74.90M	$0.22	3.50

Standard BioTools has a net margin of 100.36% compared to Evotec's net margin of -26.20%. Standard BioTools' return on equity of -7.57% beat Evotec's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Evotec	-26.20%	-24.93%	-11.35%
Standard BioTools	100.36%	-7.57%	-6.14%

In the previous week, Evotec had 6 more articles in the media than Standard BioTools. MarketBeat recorded 6 mentions for Evotec and 0 mentions for Standard BioTools. Evotec's average media sentiment score of 0.20 beat Standard BioTools' score of 0.00 indicating that Evotec is being referred to more favorably in the media.

Company	Overall Sentiment
Evotec	Neutral
Standard BioTools	Neutral

5.8% of Evotec shares are held by institutional investors. Comparatively, 53.7% of Standard BioTools shares are held by institutional investors. 1.0% of Evotec shares are held by insiders. Comparatively, 26.8% of Standard BioTools shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Summary

Evotec and Standard BioTools tied by winning 7 of the 14 factors compared between the two stocks.

Get Standard BioTools News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding LAB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

LAB vs. The Competition

Export

Metric	Standard BioTools	Life Sciences Tools & Services Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$302.21M	$10.40B	$7.24B	$13.19B
Dividend Yield	N/A	1.46%	2.57%	12.81%
P/E Ratio	3.50	70.70	274.93	25.38
Price / Sales	3.54	108.53	646.01	89.45
Price / Cash	N/A	27.47	76.25	51.42
Price / Book	0.70	5.70	10.46	6.33
Net Income	-$74.90M	$56.67B	$3.49B	$358.33M
7 Day Performance	11.57%	4.59%	0.59%	1.12%
1 Month Performance	19.11%	0.07%	-1.74%	-2.39%
1 Year Performance	-45.01%	27.93%	18.13%	5.35%

Standard BioTools Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
LAB Standard BioTools	2.3603 of 5 stars	$0.77 +5.5%	$1.35 +75.4%	-45.0%	$302.21M	$85.33M	3.50	389
CYRX CryoPort	1.8815 of 5 stars	$16.24 +1.8%	$18.00 +10.8%	+70.7%	$822.00M	$176.18M	N/A	738	News Coverage Analyst Forecast
MLAB Mesa Laboratories	1.417 of 5 stars	$122.30 +0.7%	$110.00 -10.1%	+73.0%	$682.86M	$249.13M	145.17	717	Positive News
CTKB Cytek Biosciences	1.2838 of 5 stars	$4.94 +2.3%	$5.56 +12.5%	+40.2%	$642.51M	$206.71M	N/A	702	News Coverage Gap Down
OABI OmniAb	2.9501 of 5 stars	$4.33 -3.3%	$11.00 +153.9%	+177.6%	$626.19M	$38.46M	N/A	89

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:LAB) was last updated on 9/20/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Standard BioTools (LAB) Competitors

LAB vs. CYRX, MLAB, CTKB, OABI, and EVO

How does Standard BioTools compare to CryoPort?

Summary

How does Standard BioTools compare to Mesa Laboratories?

Summary

How does Standard BioTools compare to Cytek Biosciences?

Summary

How does Standard BioTools compare to OmniAb?

Summary

How does Standard BioTools compare to Evotec?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

LAB vs. The Competition

Standard BioTools Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Standard BioTools (LAB) Competitors

LAB vs. CYRX, MLAB, CTKB, OABI, and EVO

How does Standard BioTools compare to CryoPort?

Does the media favor LAB or CYRX?

Do analysts rate LAB or CYRX?

Is LAB or CYRX more profitable?

Which has more volatility and risk, LAB or CYRX?

Which has stronger earnings and valuation, LAB or CYRX?

Do institutionals and insiders have more ownership in LAB or CYRX?

Summary

How does Standard BioTools compare to Mesa Laboratories?

Does the media prefer LAB or MLAB?

Which has more risk and volatility, LAB or MLAB?

Do insiders & institutionals believe in LAB or MLAB?

Is LAB or MLAB more profitable?

Which has better valuation and earnings, LAB or MLAB?

Do analysts rate LAB or MLAB?

Summary

How does Standard BioTools compare to Cytek Biosciences?

Do analysts recommend CTKB or LAB?

Does the media refer more to CTKB or LAB?

Do institutionals & insiders have more ownership in CTKB or LAB?

Which has more risk & volatility, CTKB or LAB?

Which has better earnings and valuation, CTKB or LAB?

Is CTKB or LAB more profitable?

Summary

How does Standard BioTools compare to OmniAb?

Do analysts recommend LAB or OABI?

Is LAB or OABI more profitable?

Do insiders & institutionals hold more shares of LAB or OABI?

Which has stronger earnings & valuation, LAB or OABI?

Which has more volatility & risk, LAB or OABI?

Does the media prefer LAB or OABI?

Summary

How does Standard BioTools compare to Evotec?

Do analysts prefer EVO or LAB?

Which has more risk & volatility, EVO or LAB?

Which has better valuation & earnings, EVO or LAB?

Is EVO or LAB more profitable?

Does the media favor EVO or LAB?

Do institutionals and insiders have more ownership in EVO or LAB?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

LAB vs. The Competition

Standard BioTools Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools